Long-Term Exposure to Ambient Fine Particulate Matter and Renal Function in Older Men: The Veterans Administration Normative Aging Study

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1289/ehp.1510269

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29407829

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Long-Term Exposure to Ambient Fine Particulate Matter and Renal Function in Older Men: The Veterans Administration Normative Aging Study

Amar J. Mehta,1 Antonella Zanobetti,1 Marie-Abele C. Bind,1 Itai Kloog,2 Petros Koutrakis,1 David Sparrow,3,4,5 Pantel S. Vokonas,3,5 and Joel D. Schwartz1,4

1Exposure, Epidemiology and Risk Program, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; 2Department of Geography and Environmental Development, Ben-Gurion University of the Negev, Beer Sheva, Israel; 3VA Normative Aging Study, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA; 4Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; 5Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA

BACKGROUND: It is unknown if ambient fine particulate matter (PM2.5) is associated with lower renal function, a cardiovascular risk factor.

OBJECTIVE: We investigated whether long-term PM2.5 exposure was associated with estimated glomerular filtration rate (eGFR) in a cohort of older men living in the Boston Metropolitan area.

METHODS: This longitudinal analysis included 669 participants from the Veterans Administration Normative Aging Study with up to four visits between 2000 and 2011 (n = 1,715 visits). Serum creatinine was measured at each visit, and eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation. One-year exposure to PM2.5 prior to each visit was assessed using a validated spatiotemporal model that utilized satellite remote-sensing aerosol optical depth data. eGFR was modeled in a time-varying linear mixed-effects regression model as a continuous function of 1-year PM2.5, adjusting for important covariates.

RESULTS: One-year PM2.5 exposure was associated with lower eGFRs; a 2.1-μg/m3 interquartile range higher 1-year PM2.5 was associated with a 1.87 mL/min/1.73 m2 lower eGFR [95% confidence interval (CI): –2.99, –0.76]. A 2.1 μg/m3-higher 1-year PM2.5 was also associated with an additional annual decrease in eGFR of 0.60 mL/min/1.73 m2 per year (95% CI: –0.79, –0.40).

CONCLUSIONS: In this longitudinal sample of older men, the findings supported the hypothesis that long-term PM2.5 exposure negatively affects renal function and increases renal function decline.


Introduction

Chronic exposure to ambient fine particulate matter (PM2.5) is a well-known risk factor for cardiovascular-related morbidity and mortality (Brook et al. 2010). Although the underlying mechanisms have not been fully elucidated, there is evidence suggesting that pathways at the molecular level, including inflammation (Ostro et al. 2014; Rückerl et al. 2014) and oxidative stress (Sørensen et al. 2003), and at the function level, including arterial blood pressure (BP) (Fuks et al. 2014; Liang et al. 2014) and vascular/endothelial function (Krishnan et al. 2012; Wilker et al. 2014), may have a role in PM2.5-related cardiovascular morbidity and mortality.

It is also hypothesized that renal function impairment may be a mediating factor of the cardiovascular effects of long-term PM2.5 exposure because the kidney is a vascularized organ susceptible to large-vessel atherosclerotic disease and microvascular dysfunction (Lue et al. 2013). Impaired renal function, as determined from the estimated glomerular filtration rate (eGFR), is also associated with cardiovascular events and mortality (Fox et al. 2012; Go et al. 2004; Sarnak et al. 2003). There is limited experimental evidence suggesting that particle exposure affects the kidney; in vivo studies in rats have shown controlled exposure to urban or diesel exhaust particles to be associated with increased cytokine expression in the kidney (Thomson et al. 2013) and to aggravate acute renal failure (Nemmar et al. 2010). A recent cross-sectional study of stroke patients living in the Boston metropolitan area found that living near a major roadway was associated with reduced eGFR (Lue et al. 2013). To our knowledge, no longitudinal population study has directly evaluated whether long-term PM2.5 exposure is associated with reduced renal function or with increased age-related decline in renal function.

We investigated whether 1-year averaged exposure to PM2.5 was associated with reduced renal function and with renal function decline over time in an ongoing prospective cohort study of older men living in the Boston metropolitan area. This study takes advantage of a longitudinal sample with serum creatinine measured at multiple visits, where renal function was characterized by creatinine-based eGFR as defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (Levey et al. 2009), as well as a validated, spatially and temporally resolved prediction model of annual outdoor exposure to PM2.5 at each participant’s home address (Kloog et al. 2011, 2014). We also investigated whether the association between PM2.5 and eGFR was mediated via a change in BP.

Methods

Participants included in this analysis were enrolled in the Veterans Administration (VA) Normative Aging Study, an ongoing longitudinal study of aging established by the VA in 1963, details of which have been published previously (Bell et al. 1972). Briefly, the VA Normative Aging Study is a closed cohort of 2,280 male volunteers from the greater Boston area (Massachusetts), 21–80 years of age at study entry, who enrolled after an initial health screening determined that they were free of known chronic medical conditions.

This work was supported by grants from the National Institute of Environmental Health Sciences, National Institutes of Health (NIH) (ES014663-01A2) and from the U.S. Environmental Protection Agency (EPA) (R832416, R82753, and R83241601). The Veterans Affairs (VA) Normative Aging Study is supported by the Cooperative Studies Program/Epidemiology Research and Information Center of the U.S. Department of Veterans Affairs and is a component of the Massachusetts Veterans Epidemiology Research and Information Center, Boston, Massachusetts. Support was also provided by NIH grants R01-AG002287, R01-AG018436, and R29-AG007465. This research was also supported by a VA Research Career Scientist award to D.S., as well as by the Ziff Fund at the Harvard University Center for the Environment awarded to M.-A.C.B.

This article’s contents are solely the responsibility of the grantee and do not necessarily represent the official views of the U.S. EPA. Further, the U.S. EPA does not endorse the purchase of any of the commercial products or services mentioned in the article.

The authors declare they have no actual or potential competing financial interests.

Received: 28 May 2015; Revised: 15 September 2015; Accepted: 23 February 2016; Published: 8 March 2016.
conditions. The study population is predominantly White; < 2% of all participants are Black. Participants have been reevaluated every 3–5 years with detailed, onsite physical examinations and questionnaires. Visits took place in the morning, after an overnight fast and smoking abstinence. The present study was approved by the human research committees of the Harvard T.H. Chan School of Public Health and the Veterans Affairs Boston Healthcare System, and written informed consent was obtained from subjects before participation.

Eligibility for this study required continued participation between May 2000 and December 2011, the period for which satellite-derived aerosol optical depth (AOD) measurements were available, and 756 participants had ≥ 1 scheduled visit during this time period (Figure 1). Of the 756 participants, we excluded 58 (7.7%) for not continuing to live within the coverage area of the prediction model, 11 (1.5%) for not having serum creatinine measured at any visit, and 18 (2.3%) for having incomplete information on covariates of interest. Thus, a total of 669 participants were included in this longitudinal repeated-measures analysis and presented for a total of 1,715 visits during the study period.

**Exposure Assessment**

We assessed long-term PM$_{2.5}$ exposure using satellite-based spatiotemporal models that predicted the daily ambient concentration of PM$_{2.5}$ at each participant’s residence. We applied our recently published (Kloog et al. 2014) high-resolution 1 × 1 km exposure model for the years for which we had prediction data (2003–2011), and we applied a slightly lower-resolution 10 × 10 km model (Kloog et al. 2011) for the years for which new model predictions were unavailable (2000–2002). The 1 × 1 km exposure assessment is based on a new multi-angle implementation to atmospheric correction (MAIAC) algorithm developed by the National Aeronautics and Space Administration (NASA) (Lyapustin et al. 2011), whereas the 10 × 10 km exposure assessment is based on the older NASA moderate resolution imaging spectroradiometer (MODIS) algorithm. The MAIAC algorithm provides finer-resolution AOD data than the MODIS algorithm, which allowed us to use a high-resolution 1 × 1 km model versus the MODIS 10 × 10 km AOD data. The 1 × 1 km and the 10 × 10 km models use similar methodology. We used a mixed-effects model approach by regressing daily PM$_{2.5}$ mass concentrations (μg/m$^3$) from the U.S. Environmental Protection Agency (EPA) Air Quality System and Interagency Monitoring of Protected Visual Environments network against the AOD, spatial predictors, and temporal predictors. For days when AOD data were not available for some grid cells, we regressed the predicted PM$_{2.5}$ for each grid cell against the PM$_{2.5}$ at the nearest monitor within 60 km of the cell and a thin-plate spline term of latitude and longitude. We used this model to fill in the missing grid cell–days. The mean out-of-sample $R^2$ values from 10-fold cross-validation were 0.88 and 0.83 for the 1 × 1 km and the 10 × 10 km models, respectively, indicating excellent prediction ability. Additional details are available in our previously published papers (Kloog et al. 2011, 2014). For each participant, we calculated address-specific exposure of 1-year averaged PM$_{2.5}$ concentrations prior to examination visit.

**Outcome Assessment**

Serum samples were drawn after overnight fasting, and serum creatinine concentration (Scr, mg/dL) was determined using a computized automatic analyzer (Technicon SAM models (Technicon Corp., Tarrytown, NY)) from 1979 to 1993; Boehringer Mannheim/Hitachi 747 analyzer (Boehringer-Mannheim Corp, Indianapolis, IN) from 1993 onward) at each examination. The analyzer measured creatinine based on the Jaffe procedure (Jaffe 1886) and showed excellent reproducibility. This method of analysis had an intraassay coefficient of variation (CV) of 1.3% at 1.2 mg/dL and an interassay CV of 3.3% at 1.1 mg/dL. We calculated eGFR at each visit using the CKD-EPI equation (eGFR = 141 × min(Scr/0.9, 1) $^{-0.411} \times$ max(Scr/0.9, 1) $^{-1.209} \times$ 0.993$^{\text{Age}} \times$ 1.159 [if Black]) (Levey et al. 2009). The calculated intraclass correlation coefficient of 0.7 for eGFR indicated a high degree of stability over time.

**Ascertainment of Covariates**

At each examination, participants underwent physical examination, their medical history was updated, and biomarkers from serum samples were measured, including fasting glucose and serum cholesterol. Serum cholesterol was assayed over the course of the study period using standard enzymatic methods and reagents (SCALVO Diagnostics, Wayne, NJ). Weight and height were measured with participants wearing only socks and underwear, from which body mass index (BMI; kg/m$^2$) was calculated. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured with a standard cuff once in each arm while the subject was seated; the mean of the right and left arm values was used for analysis. At each visit, participants were also asked to bring their current medical prescriptions; antihypertensive medication use included any of the following classes: angiotensin converting enzyme inhibitors (ACEIs), diuretics, beta blockers, angiotensin receptor blockers (ARBs), calcium channel blockers, and alpha blockers. As a proxy measure of childhood socioeconomic status, parental homeownership during the participant’s childhood was ascertained by questionnaire at the baseline survey. As a proxy measure of adult socioeconomic status, maximum years of education was ascertained by questionnaire at the early visits. Year 2000 census data were obtained from the U.S. Bureau of the Census Summary File (III) (U.S. Census Bureau 2002) at the census tract level. For this analysis, we used the proportion of the population within a census tract living below the poverty level as an area-based measure of socioeconomic status.
Long-term PM$_{2.5}$ exposure and renal function

**Statistical Analysis**

All statistical analyses were performed using SAS v.9.3 software (SAS Institute Inc., Cary, NC). We used time-varying linear mixed-effects regression models with random intercepts accounting for the correlation of repeated measures (Fitzmaurice et al. 2004) to model eGFR (mL/min/1.73 m$^2$) as a continuous function of 1-year PM$_{2.5}$, scaled per interquartile range (IQR) and adjusting for age at first visit and time since first visit (years). To evaluate whether 1-year PM$_{2.5}$ was associated with annual change in eGFR, we added an interaction between 1-year PM$_{2.5}$ and time since first visit. We additionally adjusted for the following covariates ascertained at each visit including BMI (kg/m$^2$), total cholesterol (mg/dL), coronary heart disease (no as reference), diabetes (physician-diagnosed or fasting blood glucose $\geq$ 126 mg/dL, no as reference), ARB use (no as reference), other antihypertensive medication use (no as reference), years of education ($<$ 12 years: 12 years: 13–15 years: $\geq$ 16 years as reference), percent of population in census tract living below poverty level, parental homeownership (no as reference), smoking status (current; former; never as reference), cumulative pack-years smoked, and daily alcohol intake ($\geq$ 2 drinks/day; $<$ 2 drinks/day as reference). The normality of the residuals in the linear mixed-effects model of eGFR and 1-year PM$_{2.5}$ was determined in a preliminary analysis. We also evaluated the following participant characteristics as potential effect modifiers of the association between 1-year PM$_{2.5}$ exposure and eGFR by constructing multiplicative interaction terms between each potential modifier and 1-year PM$_{2.5}$, evaluating each separately in linear mixed-effects regression models: smoking status (current or former, never), high BP (SBP $\geq$ 140 mmHg and/or DBP $\geq$ 90 mmHg), diabetes mellitus, obesity (BMI $\geq$ 30 kg/m$^2$), coronary heart disease, and use of ARB and ACEI medications. All tests for main associations and interactions for which $p < 0.05$ were considered statistically significant.

**Secondary Analyses**

Because approximately 26% of the study participants did not have a repeat visit in this analysis, we conducted a baseline cross-sectional analysis of eGFR using multiple linear regression, excluding the available repeat visits from participants. We additionally adjusted for distance to nearest major roadway, with major roadway defined as those roads having U.S. Census Feature Class Code A1 (primary highway with limited access) or A2 (primary road without limited access), as in previous studies (Auchincloss et al. 2008; Lue et al. 2013). We also adjusted for eGFR measured at first visit to evaluate its influence on the interaction between 1-year PM$_{2.5}$ and time since first visit. A total of 152 participants (~23%) began the study period with eGFR $\leq$ 60 mL/min/1.73 m$^2$, presenting for a total of 331 visits during the study period. We also examined if the association between 1-year PM$_{2.5}$ and eGFR was modified by the presence of impaired renal function (eGFR $\leq$ 60 mL/min/1.73 m$^2$) at the first visit by including an interaction term in the model.

During the study period, 223 deaths (33%) and 254 nondeath dropouts (38%) occurred (Figure 1). To account for potential selection bias by age-dependent censoring from death and from nondeath dropout before the next visit, we applied stabilized inverse probability weights analogous to methods previously applied in the NAS cohort (Power et al. 2013). Estimation of stabilized inverse probability weights for each censoring mechanism required two logistic regression models, which predicted the probability of not being censored (death, nondeath dropout) at the next visit. The first logistic regression modeled death (nondeath dropout) before the next visit as a function of 1-year PM$_{2.5}$. The second logistic regression modeled death (nondeath dropout) as a function of 1-year PM$_{2.5}$, eGFR, age, and education, adjusting for an array of clinical and sociodemographic factors that might be associated with death and/or morbidity. Given the large number of potential predictors of censoring available in this study, we used forward stepwise selection to choose variables for inclusion in these logistic regression models, setting the maximum number of variables chosen to the number of participants who died or dropped out before each visit divided by 10, while forcing in 1-year PM$_{2.5}$, renal function, age, and education-related variables. Additional variables in the models to predict censoring because of death before the next visit included the interaction between age and years of education, exclusion from pulmonary function testing for health reasons, physician’s diagnosis of emphysema, coronary heart disease, white blood cell count, smoking status, and pack-years smoked. Additional variables in the models to predict censoring because of nondeath dropout before the next visit included the interaction between age and years of education, parental homeownership, calendar year of visit, systolic blood pressure, ACEI medication use, calcium channel blocker use, statin medication use, cholesterol, serum hematicrit, fasting blood glucose, waist circumference, white blood cell count, diabetes mellitus, and current cancer diagnosis. Subsequently, we estimated stabilized inverse probability weights for censoring (death, nondeath dropout) before the next visit by taking the ratio of the probabilities estimated from the first and second logistic regression models. All weighted models met the necessary condition for correct model specification such that the mean value for the stabilized weights was approximately equal to 1 (Hernán et al. 2000). To compute a summary weight that combined the censoring by death and nondeath dropout, we simply multiplied the inverse probability weights for censoring by death and by nondeath dropout together.

Considering the evidence supporting an association between long-term PM$_{2.5}$ and BP (Fukis et al. 2014; Liang et al. 2014), and the association between BP and eGFR decline (Young et al. 2002), we hypothesized that the association between long-term PM$_{2.5}$ and reduced renal function is mediated through an increase in BP. Previously, we found that 1-year PM$_{2.5}$ was associated with higher DBP in the NAS cohort (unpublished). Using methods previously developed and applied in the NAS cohort (Bind et al. 2014, 2016), we conducted a mediation analysis and calculated the estimated mediated effect of 1-year PM$_{2.5}$ on eGFR through an increase in DBP. We simultaneously fit two time-varying linear mixed-effects models:

\[
M_{ij} = (\gamma_0 + u_i + \gamma_1 X_{ij} + \Sigma\gamma_k C_{kij} + \epsilon_{ij} \mid \epsilon_{ij} \sim N(0, \sigma^2_\epsilon) \text{ and } u_i \sim N(0, \sigma^2_u), \]  

\[
Y_{ij} = (\beta_0 + g_i) + \beta_1 X_{ij} + \beta_2 M_{ij} + \Sigma\beta_k C_{kij} + \Sigma\beta_k A_k + \eta_{ij} \mid \eta_{ij} \sim N(0, \sigma^2_\eta) \text{ and } g_i \sim N(0, \sigma^2_g), \]  

where $i$, $j$, and $k$ are defined as individuals, visits, and covariates, respectively; $M$, $X$, and $Y$ represent the DBP, 1-year PM$_{2.5}$, and eGFR, respectively; $C$ represents the set of covariates for which we adjusted, and $g$ represents the random intercept for $M$. The estimated mediated effect is given by the product formula $\gamma_1 \beta_2$. The delta method allowed us to approximate the variance of the estimated mediated effect by $\text{Var} (\gamma_1 \beta_2) = \gamma_1^2 + 2 \text{Cov}(\gamma_1, \beta_2) \gamma_1 \beta_2 + \text{Var}(\gamma_1) \beta_2^2$. The mediation formulae we have derived are valid if four identification assumptions are met, if there is no time-varying confounding with respect to the 1-year PM$_{2.5}$ and DBP (which can be achieved in situations with exogenous exposure and mediator depending only on recent values of the exposure and confounders). The four identification assumptions include a) no unmeasured 1-year PM$_{2.5}$–eGFR confounding at time $j$ given the covariates and random effects, b) no unmeasured DBP–eGFR confounding, c) no unmeasured 1-year PM$_{2.5}$–DBP confounding, and d) no DBP–eGFR confounder affected by 1-year PM$_{2.5}$. Because the measurements of the mediator and the...
outcome are taken at the same time (cross-sectionally), it is implied that the mediator does not necessarily precede the measurement of the outcome, and we cannot rule out that the outcome could be the mediator and the mediator the outcome.

**Results**

The characteristics of the participants at the first visit and over all visits are summarized in Table 1. The mean age of the participants was 73.5 years, and the majority of the participants were former smokers and used anti-hypertensive medications at the first visit. Compared with participants at the first visit, the mean eGFR was lower in participants over all visits, whereas the prevalences of coronary heart disease, hypertension, and of using anti-hypertensive medications were higher.

The mean 1-year average PM$_{2.5}$ concentrations at participant addresses at the first visit was 11.4 μg/m$^3$ (Table 1). This estimate was lower in participant addresses over all visits, whereas the mean was 10.5 μg/m$^3$. All yearly averages from 2000 to 2011 were below the U.S. annual fine particle standard, which was recently revised downward from 15 μg/m$^3$ to 12 μg/m$^3$ in 2013 (U.S. EPA 2013), and the mean and median 1-year PM$_{2.5}$ concentrations closely approximated each other (Table 2). In all person-visits over calendar year, the mean yearly average PM$_{2.5}$ concentrations increased from 10.5 μg/m$^3$ in 2000 to their highest level of 11.8 μg/m$^3$ in 2002 and later decreased to levels < 9.0 μg/m$^3$ in 2010 and 2011.

The associations between 1-year PM$_{2.5}$ and eGFR in all participants, after various adjustments, are summarized in Figure 2. One-year averaged exposure to PM$_{2.5}$ was statistically significantly ($\beta < 0.05$) associated with lower eGFR in the overall sample. In the age-adjusted model, a 2.1-μg/m$^3$ IQR higher 1-year PM$_{2.5}$ was associated with a 2.13-mL/min/1.73 m$^2$ lower eGFR [95% confidence interval (CI): –3.25, –0.76]. Relative to the age-adjusted model, the association between 1-year PM$_{2.5}$ and eGFR in the fully adjusted model was slightly attenuated; a 2.1-μg/m$^3$ IQR higher 1-year PM$_{2.5}$ was associated with a 1.87-mL/min/1.73 m$^2$ lower eGFR (95% CI: –2.99, –0.76) after adjustment for all other covariates. However, the association with the fully adjusted model was robust to additional adjustment for distance to roadway, and to inverse probability of censoring weights by death and nondeath dropout and by the combined weight of both censoring mechanisms.

There was no statistically significant effect modification by participant characteristics on the association between 1-year PM$_{2.5}$ and eGFR in all participants, after various adjustments, are summarized in Figure 2. One-year averaged exposure to PM$_{2.5}$ was associated with lower eGFR in the overall sample, as shown in Figure 2, was observed mainly for individuals not using ARB medication ($\beta$: –2.10 mL/min/1.73 m$^2$, 95% CI: –3.25, –0.95); a null association was observed for individuals using ARB medication ($\beta$: –0.28 mL/min/1.73 m$^2$, 95% CI: –2.54, –1.98). A similar pattern was observed for diabetes; the negative association between 1-year PM$_{2.5}$ and eGFR was more pronounced for non-diabetic individuals ($\beta$: –2.11 mL/min/1.73 m$^2$, 95% CI: –3.26, –0.97) than for diabetic individuals ($\beta$: –0.64 mL/min/1.73 m$^2$, 95% CI: –2.46, –0.93) ($p_{interaction}$ = 0.09). After additional adjustment for the 1-year PM$_{2.5}$–ARB interaction in the model, there was less contrast in the 1-year PM$_{2.5}$–eGFR association between diabetic ($\beta$: –1.00 mL/min/1.73 m$^2$, 95% CI: –2.91, 0.90) and non-diabetic subgroups ($\beta$: –2.27 mL/min/1.73 m$^2$, 95% CI: –3.44, 1.10) ($p_{interaction}$ = 0.16). In contrast to the observations for diabetes, the negative associations between 1-year PM$_{2.5}$ and eGFR were more pronounced for individuals presenting with obesity ($\beta$: –2.64 mL/min/1.73 m$^2$, 95% CI: –4.25, –1.03) and with high BP ($\beta$: –2.71 mL/min/1.73 m$^2$, 95% CI: –4.36, –1.05) than for individuals who did not present with obesity ($\beta$: –1.63 mL/min/1.73 m$^2$, 95% CI: –2.80, –0.46) or with high BP ($\beta$: –1.62 mL/min/1.73 m$^2$, 95% CI: –2.77, –0.46) ($p_{interaction}$ = 0.20 and $p_{interaction}$ = 0.17 for obesity and high BP, respectively).

One-year PM$_{2.5}$ was associated with a higher rate of decline in eGFR over time; an interaction was identified between time since first visit and 1-year PM$_{2.5}$ ($p_{interaction}$ < 0.0001) (Figure 4). After adjustment for all covariates, a 2.1-μg/m$^3$ higher 1-year PM$_{2.5}$ was associated

---

**Table 1.** Characteristics of participants at first visit and over all visits [mean ± SD or n (%)].

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>First visit</th>
<th>All visits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>73.5 ± 6.8</td>
<td>75.9 ± 6.8</td>
</tr>
<tr>
<td>eGFR (CKD-EPI), mL/min/1.73 m$^2$</td>
<td>71.0 ± 15.7</td>
<td>68.0 ± 16.2</td>
</tr>
<tr>
<td>Body mass index, kg/m$^2$</td>
<td>28.2 ± 4.1</td>
<td>27.9 ± 4.2</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL</td>
<td>1.1 ± 0.5</td>
<td>1.1 ± 0.5</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>195.5 ± 38.5</td>
<td>183.8 ± 38.3</td>
</tr>
<tr>
<td>Years of education</td>
<td>15.0 ± 3.0</td>
<td>15.1 ± 2.9</td>
</tr>
<tr>
<td>Percent below poverty level (census tract 1999)</td>
<td>6.1 ± 5.6</td>
<td>6.0 ± 5.4</td>
</tr>
<tr>
<td>PM$_{2.5}$ (1-year average), μg/m$^3$</td>
<td>11.4 ± 1.0</td>
<td>10.5 ± 1.4</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>31 (5)</td>
<td>55 (3)</td>
</tr>
<tr>
<td>Former</td>
<td>450 (67)</td>
<td>1,160 (68)</td>
</tr>
<tr>
<td>Never</td>
<td>188 (28)</td>
<td>500 (29)</td>
</tr>
<tr>
<td>Daily alcohol intake</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 2 drinks/day</td>
<td>124 (19)</td>
<td>315 (18)</td>
</tr>
<tr>
<td>&lt; 2 drinks/day</td>
<td>545 (81)</td>
<td>1,400 (82)</td>
</tr>
<tr>
<td>Parents owned home</td>
<td>250 (37)</td>
<td>643 (37)</td>
</tr>
<tr>
<td>Obese (≥ 30 kg/m$^2$)</td>
<td>175 (26)</td>
<td>438 (26)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>117 (17)</td>
<td>323 (19)</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>204 (30)</td>
<td>597 (35)</td>
</tr>
<tr>
<td>Hypertension diagnosis</td>
<td>474 (71)</td>
<td>1,298 (76)</td>
</tr>
<tr>
<td>High blood pressure (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90)</td>
<td>186 (28)</td>
<td>402 (23)</td>
</tr>
<tr>
<td>Angiotensin receptor blocker medication use</td>
<td>31 (5)</td>
<td>144 (8)</td>
</tr>
<tr>
<td>Angiotensin converting enzyme inhibitor medication use</td>
<td>188 (28)</td>
<td>625 (36)</td>
</tr>
<tr>
<td>Other antihypertensive medication use (calcium channel blockers, beta blockers, or alpha blockers)</td>
<td>378 (57)</td>
<td>1,067 (64)</td>
</tr>
</tbody>
</table>

**Table 2.** Distribution of 1-year PM$_{2.5}$ concentrations over all visits by calendar year.

<table>
<thead>
<tr>
<th>Year</th>
<th>Visits (n)</th>
<th>Mean (SD)</th>
<th>Median (25th percentile, 75th percentile)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>141</td>
<td>10.5 (0.8)</td>
<td>10.5 (9.9, 11.0)</td>
</tr>
<tr>
<td>2001</td>
<td>245</td>
<td>11.8 (0.7)</td>
<td>11.7 (11.3, 12.3)</td>
</tr>
<tr>
<td>2002</td>
<td>223</td>
<td>11.8 (0.6)</td>
<td>11.9 (11.5, 12.2)</td>
</tr>
<tr>
<td>2003</td>
<td>106</td>
<td>11.7 (0.8)</td>
<td>11.7 (11.4, 12.2)</td>
</tr>
<tr>
<td>2004</td>
<td>169</td>
<td>10.8 (0.9)</td>
<td>10.8 (10.4, 11.3)</td>
</tr>
<tr>
<td>2005</td>
<td>193</td>
<td>10.8 (1.0)</td>
<td>11.0 (10.4, 11.4)</td>
</tr>
<tr>
<td>2006</td>
<td>126</td>
<td>10.2 (0.9)</td>
<td>10.2 (9.7, 10.8)</td>
</tr>
<tr>
<td>2007</td>
<td>116</td>
<td>9.9 (0.9)</td>
<td>9.3 (9.0, 9.8)</td>
</tr>
<tr>
<td>2008</td>
<td>147</td>
<td>10.1 (0.9)</td>
<td>10.2 (9.7, 10.7)</td>
</tr>
<tr>
<td>2009</td>
<td>104</td>
<td>9.0 (0.9)</td>
<td>9.0 (8.6, 9.5)</td>
</tr>
<tr>
<td>2010</td>
<td>93</td>
<td>8.0 (1.0)</td>
<td>8.0 (7.5, 8.5)</td>
</tr>
<tr>
<td>2011</td>
<td>102</td>
<td>8.4 (0.8)</td>
<td>8.5 (8.1, 9.0)</td>
</tr>
</tbody>
</table>

Abbreviations: CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate; PM$_{2.5}$, particulate matter ≤ 2.5 μm in diameter.
with an additional annual decrease in eGFR of 0.60 mL/min/1.73 m²/year (95% CI: –0.79, –0.40). This association was robust to additional adjustments for distance to roadway and for eGFR measured at the first visit, and to inverse probability of censoring weights by death and nondeath dropout and by the combined weight of both censoring mechanisms.

**Secondary Analyses**

Similar findings were observed for the association between 1-year PM2.5 and eGFR from the baseline cross-sectional analysis; in the fully adjusted model, a 2.1-μg/m³ higher 1-year PM2.5 was associated with a 1.63-mL/min/1.73 m² lower eGFR (95% CI: –3.78, 0.51). No significant effect modification ($p_{interaction} = 0.27$) was observed for impaired renal function at the first visit on the association between 1-year PM2.5 and eGFR; negative associations between 1-year PM2.5 and eGFR were observed for individuals who began the study period with ($β$: –2.47, –0.35) impaired renal function. Similarly, age-related decline in eGFR associated with 1-year PM2.5 was observed for individuals who began the study period with ($β$: –0.53 mL/min/1.73 m²/year, 95% CI: –0.74, –0.33) and without ($β$: –0.65 mL/min/1.73 m²/year, 95% CI: –0.84, –0.46) impaired renal function. For the mediation analysis, we observed that a 2.1 μg/m³ increase in 1-year PM2.5 was associated with an estimated 0.14-mL/min/1.73 m² lower eGFR (95% CI: –0.28, –0.01) through a 1-mmHg increase in DBP, assuming that the identification assumptions were met and that there was no time-varying confounding with respect to 1-year PM2.5 and DBP.

**Discussion**

The novel findings from this prospective cohort study of older men indicate that 1-year PM2.5 exposure is associated with reduced eGFR and an increased rate of eGFR decline over time. These associations were robust to various sensitivity analyses. There was no statistically significant effect modification by participant characteristics on the association between 1-year PM2.5 and eGFR, but the associations were null for ARB users and for diabetics. The association between 1-year PM2.5 and eGFR was also mediated by an increase in DBP, although this finding is based on some unverifiable assumptions.

To date, there has been limited research on the relationship between long-term exposure to particulate matter air pollution and renal-related outcomes. A recent
cross-sectional study of 1,103 stroke patients in the Boston metropolitan area found that participants living < 50 m from a major roadway had a 3.9-mL/min/1.73 m² lower eGFR (95% CI: −1.0, −6.7) than participants who lived >1,000 m away (Lue et al. 2013). An earlier longitudinal analysis of 3,901 participants within the Multi-Ethnic Study of Atherosclerosis reported that chronic exposures to PM$_{2.5}$ and PM$_{10}$, which were averaged over 20 years, were not associated with the urinary albumin/creatinine ratio, although there was an elevated risk of microalbuminuria associated with chronic PM$_{10}$ exposure that was of marginal statistical significance (O’Neill et al. 2008).

Although we did not identify a statistically significant interaction between 1-year PM$_{2.5}$ and ARB use, it is of interest that the association between 1-year PM$_{2.5}$ and eGFR was null for ARB users. ARBs, alone or in combination with ACEIs, have been shown to slow the progression of chronic kidney disease in individuals with or without diabetes, independent of their blood pressure–lowering effect (Palmer et al. 2015). Findings from experimental in vivo and in vitro studies also suggest that ARBs may minimize the oxidative stress and vasoconstrictive effects of PM (Ghelfi et al. 2010; Li et al. 2005). Here, we observed that the negative association between 1-year PM$_{2.5}$ and eGFR was stronger for obese participants but weaker for diabetic participants, which was unexpected. The pattern of effect modification by diabetes was similar to that of ARB use, and in this study, the prevalence of ARB use was two times greater in diabetic (36%) than in nondiabetic participants (18%).

The underlying biological mechanism(s) that may explain the novel association between long-term PM$_{2.5}$ exposure and lower eGFR and higher eGFR decline are not known. We hypothesize that the negative association between 1-year PM$_{2.5}$ exposure and eGFR was mediated by an increase in DBP, and the result from the mediation analysis appears consistent with that hypothesis. If the assumptions of the causal mediation analysis hold, the small magnitude of the estimated mediated effect for PM$_{2.5}$ also suggests that the association between 1-year PM$_{2.5}$ and eGFR is likely only partially mediated by DBP and that there may be nonhemodynamic pathways to consider. Previous studies have revealed associations between long-term PM$_{2.5}$ exposures and vascular/endothelial dysfunction (Hoffmann et al. 2007; Krishnan et al. 2012; Wilker et al. 2014). In addition, observational evidence supports the associations between markers of vascular/endothelial dysfunction and serum creatinine–derived eGFR decline (Foster et al. 2013; Perticone et al. 2010). 

Taking these findings together, we also hypothesize that the associations between 1-year PM$_{2.5}$ and both eGFR and eGFR decline are possibly mediated by pathways associated with vascular/endothelial dysfunction.

The clinical relevance of the present findings merits further discussion. The difference in eGFR for a 2.1-µg/m³ increase in 1-year PM$_{2.5}$ is comparable in magnitude to the reduction in eGFR observed for a 2-year increase in age in this cohort (β: −1.8 mL/min/1.73 m², 95% CI: −2.1, −1.5). In the context of eGFR decline, a rapid decline in creatinine-based eGFR of ≥ 3 mL/min/1.73 m² per year in older adults has been shown to be associated with a 70% higher risk of cardiovascular mortality (Rifkin et al. 2008). Extrapolating our findings for a 10-µg/m³ increase, which may be more appropriate in more polluted settings, may result in a more clinically meaningful estimate of association for eGFR decline, particularly in older populations.

This study has a number of strengths, including a prospective design to investigate the role of PM$_{2.5}$ exposure on repeated measures of serum creatinine–derived eGFR, the use of validated spatiotemporal models for assessment of PM$_{2.5}$, advanced methods to address potential bias from age-dependent censoring by death and nondeath dropout, and adjustment for multiple potential confounders and individual-level risk factors. However, there are limitations to consider in this study. Although the CKD-EPI equation for estimating eGFR has shown clinical utility in risk prediction of end-stage renal disease and cardiovascular outcomes (Matsushita et al. 2010), there is an inherent physiologic limitation to using serum creatinine as a marker of kidney filtration (Shemesh et al. 1985).

Non-GFR determinants of eGFR, including muscle mass and diet, may lead to overestimation of serum creatinine, particularly for individuals with preserved renal function, and future studies should consider using alternative agents for estimation of eGFR including cystatin C (Fan et al. 2014). We hypothesize that any error in measurement of eGFR is likely independent of the 1-year PM$_{2.5}$ predictions assigned to the participants in the present study and would result in bias.
of the true association between 1-year PM2.5 and eGFR toward the null. The potential for reverse causation, particularly between DBP and eGFR, is not theoretical and is also a limitation of our mediation findings; there is limited observational evidence suggesting that reduced eGFR may precede elevation in blood pressure and onset of hypertension (Kestenbaum et al. 2008; Takase et al. 2012). Potential risk factors or confounding variables included in our models, such as diabetes status and BMI, may also be intermediate variables. Additionally, there may be some unmeasured confounding from other factors associated with eGFR that may be correlated with PM2.5 exposure in this study, such as environmental noise. Traffic, aircraft, and railway noise has been shown to be associated with markers of cardiovascular disease (Münzel et al. 2014), but whether environmental noise is associated with renal function is unknown. However, our association persisted after controlling for distance to major roadway, which is a marker for traffic-related pollution including noise. Finally, this study consists of older men who are predominantly White and reside in a lightly polluted area. The observed findings may not be generalizable to women, younger individuals, other racial and ethnic groups, or people living in other areas owing to differential environmental and physiological factors.

Conclusion

In summary, we found that long-term PM2.5 exposure was associated with reduced eGFR and increased age-related eGFR decline in this longitudinal sample of predominantly older White men. These findings support the hypothesis that long-term PM2.5 exposure negatively affects renal function and renal function decline. These findings should be verified in other study populations with longitudinal follow-up.

References


